EUCTR2010-018374-20-BE进行中（未招募）1 期
A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients with Recent Onset Symptomatic Atrial Fibrillation
Cardiome UK Limited0 个研究点目标入组 450 人开始时间: 2010年7月22日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject is eligible for the study if all of the following apply:
- •1. Institutional Review board (IRB)-/Independent Ethics Committee (IEC)- approved written Informed Consent and privacy language as per national regulations (e.g. HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable);
- •2. Subject must be between the ages of 18 and 85, inclusive;
- •3. Females must be not pregnant or nursing and if pre-menopausal, must be using an effective form of birth control from time of screening until 30 days post study treatment;
- •4. Subject must have recent onset (> 3 hours to less than or equal to 7 days) symptomatic AF determined by the Investigator to be best managed by acute conversion to SR. The presence of atrial fibrillation will be documented by a 12-lead ECG recording at Screening and Baseline;
- •5. Subject must have, in the judgment of the Investigator, adequate anticoagulant therapy (AF has lasted more than 48 hours, subjects should be managed in accordance with standard of practice as recommended by ACC/AHA/ESC practice guidelines)
- •6. Subject must have systolic blood pressure (SBP) above 90 mmHg and less than 160 mmHg and diastolic blood pressure (DBP) less than 95 mmHg at Screening (single measurement) and Baseline (mean of triplicate measurements);
- •7. Subject must be, in the judgment of the Investigator, adequately hydrated and have a normal saline IV established and infusing;
- •8. Subject must have a body weight between 45 and 136 kg, inclusive (99 and 300 lbs).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subject will be excluded from participation if any of the following apply:
- •1. Subject has a history of heart failure or documentation of left ventricular dysfunction evidenced by any of the following:
- •a- History of heart failure defined as physician documentation or report of any of the following symptoms of heart failure before this care encounter, described as dyspnea, fluid retention, and/or low cardiac output secondary to cardiac dysfunction; or the description of rales, jugular venous distension, or pulmonary edema. A previous hospital admission with diagnosis of heart failure is considered evidence of heart failure history
- •b- Objective evidence of heart failure during the present care encounter with documentation of rales, jugular venous distension, or pulmonary edema.
- •c- Left ventricular dysfunction defined as an ejection fraction of less than 40%, if available. An echocardiogram is not required for enrollment in this study.
- •2. Subject has known or suspected prolonged QT or uncorrected QT interval of > 0.440 sec. as measured at Screening on a 12-lead ECG, familial long QT syndrome, or previous Torsade de Pointes;
- •3. Subject has symptomatic bradycardia or ventricular rate less than 50 bpm documented by 12-lead ECG at Screening, unless controlled by a pacemaker;
- •4. Subject has bradycardia (heart rate less than 50 bpm) or hypotension (SBP less that 90 mmHg) after receiving a loading, bolus dose, or sustained infusion of any rate control medication during Screening;
- •5. Subject has a QRS interval > 0.14 sec., unless subject has a pacemaker;
- •6. Subject had a myocardial infarction (MI), acute coronary syndrome, cardiac surgery
- •(including PTCA or stent placement), within 30 days prior to enrollment or subject has evidence of new ischemic changes on Screening 12-lead ECG;
- •7. Subject has troponin I or T levels beyond the upper limit of normal for the local lab at
- •8. Subject has significant valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis;
- •9. Subject has failed electrical cardioversion for AF at anytime;
- •10. Subject has failed pharmacologic conversion with an intravenous Class I or Class III antiarrhythmic drug for this episode of AF;
- •11. Subject has any known reversible causes of AF such as alcohol intoxication, pulmonary embolism, hyperthyroidism, acute pericarditis or hypoxemia (oxygen saturation less than
- •90% of room air);
- •12. Subject has uncorrected electrolyte imbalance (serum potassium less than 3.5 mmol/L must be corrected and documented 6 hours or less prior to enrollment, hypomagnesemia of any level is an exclusion);
- •13. Subject has clinical evidence of digoxin toxicity in the opinion of the Investigator;
- •14. Subject has a history of clinically significant illness (e.g. neurological, gastrointestinal, renal, hepatic, pulmonary, metabolic, endocrine, hematological, or psychiatric), medical condition or laboratory abnormality within 4 weeks prior to Screening, that in the Investigator’s opinion, would preclude the subject from participating in the trial;
- •15. Subject is unable to communicate well with the Investigator and to comply with the requirements of the entire study;
- •16. Subject has previously participated in a vernakalant study, is concurrently participating in another drug study, or has received an investigational drug within 30 days prior to Screening.
研究者
相似试验
进行中（未招募）
1 期
A Study in Patients with Chronic Cluster HeadacheEUCTR2014-005429-11-BEEli Lilly and Company162
进行中（未招募）
1 期
A study to investigate the efficacy of Anti-Bet v 1 Monoclonal Antibodies in reducing symptoms of seasonal allergic rhinitisBirch Pollen AllergyEUCTR2020-004094-52-BERegeneron Pharmaceuticals, Inc.353
进行中（未招募）
1 期
Effectiveness and Safety of Vedolizumab SC as Maintenance Therapy in Ulcerative Colitislcerative ColitisMedDRA version: 20.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000016670EUCTR2015-000480-14-CZTakeda Development Centre Europe, Ltd.400
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in patients with Advanced Non-Small Cell Lung Cancer (NSCLC)Treatment of malignancy associated weight loss or anorexia in patients with NSCLCEUCTR2018-002926-22-HUHelsinn Healthcare SA316
进行中（未招募）
不适用
Tasquinimod for metastatic castrate-resistant prostate cancerMetastatic Castrate-Resistant Prostate CancerMedDRA version: 14.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021870-12-EEActive Biotech AB1,200